The groups were similar in terms of sex and mean age. Major depression was the most frequent diagnosis in both groups. The number of ECT treatments in the propofol anesthesia group (mean 9.67, SD 2.99) did not differ significantly from the nonanesthesia group
Dear Editor: Nausea appears to be a dosagerelated side effect in as many as 26% of patients treated with selective serotonin reuptake inhibitors (SSRIs) (1, 2) . SSRIs increase the concentration of serotonin (5-HT) at neuronal synapses. Emesis may result from subsequent activation of central or peripheral 5-HT 3 receptors (2,3). Antagonism of 5-HT 3 by drugs like ondansetron is known to reduce emesis in chemotherapy patients and may have some application in SSRI-induced nausea, but the effect is short-lived and the cost is prohibitive (2,3). The 5-HT antagonist cyproheptadine may have some efficacy for SSRI-induced nausea, but it has been associated with worsening of depressive symptoms when used to treat SSRI-induced sexual dysfunction (4). The antidepressant mirtazapine, an antagonist at presynaptic alpha 2 adrenergic inhibitory autoreceptors and heteroreceptors (where it enhances noradrenergic and serotonergic activity), is also a potent antagonist of 5-HT 2 and 5-HT 3 receptors (5). We report a case of SSRI-induced nausea successfully treated with mirtazapine.
Case Report
Ms K, aged 46 years, is a single white woman who has suffered for 10 years from a recurrent unipolar major depressive disorder associated with insomnia; she also suffers from obsessive-compulsive disorder (OCD). For the last 3 years, her symptoms have been partly controlled with sertraline 300 mg daily, bupropion slow release 150 mg twice daily, and trazodone 100 mg at bedtime. During treatment, she experienced recurring episodes of nausea associated with the administration of SSRIs. With sertraline, the nausea was partly controlled by her taking the dosage in 100 mg increments 3 times daily, approximately one-third of the way into a meal. Despite these efforts, her symptoms were occasionally sufficient to cause projectile vomiting, which forced her to reduce her total daily dosage. Attempts to decrease the sertraline dosage permanently increased her OCD symptoms.
To control her nausea, mirtazapine 15 mg at bedtime was substituted for trazodone. Nausea symptoms decreased the day after starting mirtazapine and completely disappeared within 4 days. However, she had difficulty sleeping and had to restart her trazodone. The combination of mirtazapine and trazodone left her with excess daytime sedation plus restless legs when falling asleep. Mirtazapine was subsequently discontinued, and her nausea returned within 4 days. Resumption of mirtazapine 15 mg at bedtime once more relieved all nausea. Replacement of trazodone with clonazepam 0.5 mg at bedtime allowed her to have a good sleep with no daytime sedation and no restless legs.
Discussion
We describe a patient who experienced resolution of SSRI-induced nausea with lowdosage mirtazapine. The use of this agent to control nausea associated with SSRIs was first discussed by Pedersen and others in 1997 (6) . In their report, 3 patients experienced relief of nausea approximately 2 to 3 days after the addition of mirtazapine 15 mg daily. In 2 patients, nausea resumed when mirtazapine was discontinued and lessened when it was restarted. We observed a similar pattern in our case.
Effects of Propofol on Electroconvulsive Therapy Seizure Duration
Dear Editor: Propofol is an anesthetic agent alternative to methohexital. It is widely used because it is associated with smaller hemodynamic response during electroconvulsive therapy (ECT) (1) . Studies have shown that propofol reduces seizure duration, and reports of reduced seizure duration with ECT under propofol anesthesia have led to concerns that propofol may diminish the efficacy of this treatment (2,3). However, although propofol has been associated with shorter seizures when given for ECT anesthesia, the reduced seizure duration has not been associated with smaller therapeutic effect when compared with methohexital anesthesia (4, 5) .
We compared the effects of propofol on seizure duration with ECTs performed without anesthesia. We retrospectively studied 26 patients consecutively referred for ECT. All patients were hospitalized and treated in Trakya University Psychiatry Clinic, Edirne, Turkey, between January 1, 2001, and December 31, 2003. Until March 2002, ECT treatments in this clinic were performed without anesthesia. Of the 26 patients, 15 had ECT treatments under anesthesia, and 11 had treatments without anesthesia. Propofol was used as an anesthetic agent and succinylcholine was used as a muscle relaxant in the 15 patients who received anesthesia. Patients in both groups were treated with the same ECT machine (Thymatron TM DGx, Somatics Inc, Lake Bluff, IL). Bilateral electrode placement was applied for all patients. Seizure duration measurements were based on the machine's automated seizure duration determinations. The groups were compared without taking into consideration the patients' diagnosis, the drugs that they used, or their psychiatric outcomes.
